LP
HAE icon

Longaeva Partners’s Haemonetics HAE Stock Holding History

Longaeva Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Buy
+163,822
New +$10.5M 0.27% 100

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Longaeva Partners's HAE Position: Q2 2026 in Review

Longaeva Partners opened a new position in Haemonetics (HAE) in Q2 2026: 163,822 shares worth $12.3M. The stake represents 0.27% of the portfolio and ranks #100 among its holdings.

329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Longaeva Partners held 163,822 shares of Haemonetics worth $12.3M as of Q2 2026.
  • Haemonetics was a new Longaeva Partners position in Q2 2026.
  • Haemonetics made up 0.27% of Longaeva Partners's portfolio in Q2 2026, its #100 holding.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.